Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Crizotinib is approved to treat advanced ALK-positive non-small-cell lung cancer (NSCLC), but most patients ultimately develop progressive disease (PD). We investigated whether continuing ALK inhibition with crizotinib beyond PD (CBPD) is clinically beneficial and attempted to identify clinicopathol...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2014-02, Vol.25 (2), p.415-422
Hauptverfasser:	Ou, S.-H. I., Jänne, P.A., Bartlett, C.H., Tang, Y., Kim, D.-W., Otterson, G.A., Crinò, L., Selaru, P., Cohen, D.P., Clark, J.W., Riely, G.J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - enzymology Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged ALK-positive NSCLC Anaplastic Lymphoma Kinase Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Crizotinib Disease Progression Female Humans Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medical sciences Middle Aged Molecular Targeted Therapy Multiple tumors. Solid tumors. Tumors in childhood (general aspects) oncogene addiction Pharmacology. Drug treatments Pneumology Proportional Hazards Models Pyrazoles - pharmacology Pyrazoles - therapeutic use Pyridines - pharmacology Pyridines - therapeutic use Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Receptor Protein-Tyrosine Kinases - metabolism RECIST Retrospective Studies TKI treatment beyond disease progression Treatment Outcome Tumors Tumors of the respiratory system and mediastinum Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!